HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ: AKBA ) with a Buy and maintains $6 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.